MPI
VRTX icon

Mairs & Power Inc’s Vertex Pharmaceuticals VRTX Stock Holding History

Mairs & Power Inc’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-755
Closed -$263K – 234
2023
Q3 		$263K Buy
755
+100
+15% +$35K ﹤0.01% 192
2023
Q2 		$231K Buy
+655
New +$221K ﹤0.01% 209

Other funds holding VRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Mairs & Power Inc's VRTX Position: Q4 2023 in Review

Mairs & Power Inc sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 755 shares — an estimated $263K sold.

Mairs & Power Inc first reported a position in VRTX in Q2 2023 and held it in 2 quarters. The position peaked at $263K in Q3 2023. 1,439 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

  • Mairs & Power Inc reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Mairs & Power Inc sold 755 Vertex Pharmaceuticals shares in Q4 2023, an estimated $263K.
  • Mairs & Power Inc first reported a position in Vertex Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Mairs & Power Inc's Vertex Pharmaceuticals position peaked at $263K in Q3 2023.
  • 1,439 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Mairs & Power Inc's 13F filing for Q4 2023, filed 14 Feb 2024.